½ÃÀ庸°í¼­
»óǰÄÚµå
1471968

¼¼°èÀÇ ½Å°æÁ¶Àý ±â±â ½ÃÀå : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ¼¼°è, Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® - À¯Çüº°, ¿ëµµº°, »ýüÀç·áº°, ÃÖÁ¾ »ç¿ëÀÚº°

Neuromodulation Devices Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, Biomaterial, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ½Å°æÁ¶Àý ±â±â ½ÃÀå ±Ô¸ð´Â 2022³â¿¡ 57¾ï 3,000¸¸ ´Þ·¯¿¡ À̸£·¶°í, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.2%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç 2030³â¿¡´Â 116¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

½Å°æ Á¶Àý ÀåÄ¡´Â ½Å°æ°èÀÇ È°µ¿À» Á¶Á¤ÇÒ ¼ö ÀÖ´Â ¼±Áø ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÌ ±â¼úÀº µð½ºÅä´Ï¾Æ, ÆÄŲ½¼º´, ÁøÀü µîÀÇ ¿îµ¿ Àå¾Ö, À̸í, °­¹Ú¼º Àå¾Ö, Áö°¢ Àå¾Ö, °£Áú, ¹æ±¤ Á¦¾î, µÎÅë, ¸¸¼º ÅëÁõ, ³úÁ¹Áß, ÃÖ¼Ò ÀÇ½Ä »óÅÂ, °æ·Ã, ô¼ö ¼Õ»ó µîÀÇ Ä¡·á¿¡ »ç¿ë µË´Ï´Ù.

WHO¿¡ µû¸£¸é 2022³â¿¡´Â ¹Ì±¹¿¡¼­ 5,000¸¸ °ÇÀÇ °£Áú »ç·Ê, 10¾ï °ÇÀÇ ÆíµÎÅë Áõ·Ê, 40¸¸ °ÇÀÇ Ã´¼ö ¼Õ»ó »ç·Ê°¡ ±â·ÏµÇ¾ú½À´Ï´Ù. ô¼ö ÀÚ±ØÀº ¸¸¼º ¿äÅëÀÇ Ä¡·á¿¡¼­ °¡Àå ¼±È£µÇ´Â ÀýÂ÷ Áß ÇϳªÀÌÁö¸¸, ÁÖµÈ ÀÌÀ¯´Â ÅëÁõÀÇ °¨°¢À» Á¶ÀýÇϴ ô¼ö ½Å°æÀÇ ÇØºÎÇÐ ¹× ±â´ÉÀû ´É·ÂÀÔ´Ï´Ù. ô¼ö ¼Õ»óÀÇ ¹ß»ý·üÀº Áö³­ 10³â°£ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. National Spinal Cord Injury Statistical Center(NSCISC) 2021³â ÆÑÆ® ½ÃÆ®¿¡ µû¸£¸é ô¼ö ¼Õ»óÀÇ ¿¬°£ ¹ß»ý·üÀº 100¸¸ ¸í´ç 60¸íÀÔ´Ï´Ù. 2022³â 4¿ù¿¡ ¹ßÇ¥µÈ Epidemiology of traumatic spinal cord injuries: a large population-based study¶ó´Â Á¦¸ñÀÇ ³í¹®¿¡ µû¸£¸é ¿Ü»ó¼º ô¼ö ¼Õ»óÀÇ Àü ¿¬·É ¼ºº° Ç¥ÁØÈ­ ÀÌȯÀ²Àº Àα¸ 100¸¸¸í´ç 26.5¸íÀ¸·Î ³²³à ¸ðµÎ ¿¬·É°ú °ü°è°¡ ÀÖ¾ú½À´Ï´Ù. ÀÌ Ãâó¿¡ µû¸£¸é °í·ÉÀÚ(65¼¼ ÀÌ»ó)¿¡¼­´Â ³²¼º¿¡¼­ 100¸¸¸í´ç 59.2¸í, ¿©¼º¿¡¼­ 23.3¸íÀ¸·Î µÇ¾î ÀÖ½À´Ï´Ù. ô¼ö ÀÚ±Ø ÀåÄ¡´Â ô¼ö ¼ö¼ú°ú °ü·ÃµÈ ¼ö¼ú ÈÄ ÅëÁõ °ü¸®¿¡ À¯¿ëÇÕ´Ï´Ù. ô¼ö ¼ö¼ú °Ç¼ö Áõ°¡°¡ ô¼ö ÀÚ±Ø ÀåÄ¡ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ³ëÀΰú ¼ºÀο¡¼­ ô¼ö ¼Õ»óÀÇ ¹ß»ý·üÀÌ ³ô¾Æ ½Å°æ Á¶Àý ÀåÄ¡ ¼ö¿ä¸¦ ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù.

½Å°æÁ¶Àý ±â±â ½ÃÀåÀÇ ¿ëµµº° ÀλçÀÌÆ®

½Å°æÁ¶Àý ±â±â ½ÃÀåÀº ¿ëµµº°·Î ³ú½ÉºÎÀڱؿä¹ý(DBS), õ°ñ½Å°æÀÚ±Ø(SNS), À§Àü±âÀÚ±Ø(GES), ô¼öÀÚ±Ø(SCS), ¹ÌÁֽŰæÀÚ±Ø(VNS)À¸·Î ±¸ºÐµË´Ï´Ù. ô¼ö ÀÚ±Ø ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç, 2022-2030³â »çÀÌ¿¡ ½ÃÀå¿¡¼­ °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ô¼ö ÀÚ±ØÀº ¼ö³â ÀüºÎÅÍ »ç¿ëµÇ¾î ¿ÔÀ¸¸ç Áõ»óÀÌ Áõ°¡ÇÏ´Â °æ¿ì ±ÇÀåµË´Ï´Ù. Àڱà °æºÎ ¹× ¿äÃß ½Å°æ±Ù¿°, µî ¼ö¼ú ½ÇÆÐ ÁõÈıº, º¹ÇÕ¼º ±¹¼Ò ÅëÁõ ÁõÈıº, ½Å°æ Àå¾Ö µîÀºÀÌ Ä¡·á¸¦ Áö¿øÇÒ ¼öÀÖ´Â ¸î °¡Áö Áõ»óÀÔ´Ï´Ù. ô¼ö ÀÚ±ØÀº ¸¸¼º ÅëÁõ °ü¸®¿¡ È¿°úÀûÀÌ¸ç ¾ÈÀüÇÏ¸ç ºñ¿ë È¿°úÀûÀÔ´Ï´Ù. »õ·Î¿î ô¼ö ÀÚ±Ø ±â¼úÀº ³»Àå ÅëÁõ°ú ÇãÇ÷¼º ÅëÁõ°ú °°Àº ÀÓ»ó ÀûÀÀÀ» È®´ëÇϰí ÀÖÀ¸¸ç, È¿´ÉÀÌ ´õ¿í Çâ»óµÉ ¼ö ÀÖ½À´Ï´Ù.

½Å°æÁ¶Àý ±â±â ½ÃÀåÀÇ »ýüÀç·áº° ÀλçÀÌÆ®

»ýü Àç·á¿¡ µû¶ó ½Å°æ Á¶Àý ÀåÄ¡ ½ÃÀåÀº ±Ý¼Ó, °íºÐÀÚ, ¼¼¶ó¹ÍÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â ±Ý¼Ó ºÎ¹®ÀÌ ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù. ±×·¯³ª °íºÐÀÚ ºÎ¹®Àº 2022-2030³â¿¡ °¡Àå ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °Í °°½À´Ï´Ù. ½Å°æÁ¶Àý ±â±â¿¡¼­´Â ƯÈ÷ ³ôÀº ³»±¸¼º°ú Àüµµ¼ºÀ» ÇÊ¿ä·Î ÇÏ´Â Àü±Ø ¹× ±âŸ ºÎǰ¿¡ ±Ý¼Ó°è »ýüÀç·á°¡ ÀÚÁÖ ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶Ù¾î³­ °­µµ ´ë Áß·®ºñ¿Í Ź¿ùÇÑ »ýüÀûÇÕ¼ºÀ¸·Î ÀÎÇØ ƼŸ´½°ú ÇÕ±ÝÀº ½Å°æÁ¶Àý ±â±â¿¡ ÀÚÁÖ »ç¿ëµË´Ï´Ù.

Áúº´°ü¸®¿¹¹æ¼¾ÅÍ, ºê¶óÁú½Å°æ°úÇÐ,½Å°æ±â¼ú¿¬±¸¼Ò´Â ½Å°æÁ¶Àý ±â±â ½ÃÀå¿¡ °üÇÑ º¸°í¼­¸¦ ÀÛ¼ºÇÒ ¶§ ÂüÁ¶ÇÑ ÁÖ¿ä 1Â÷ ¹× 2Â÷ Á¤º¸ÀÇ ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ½Å°æÁ¶Àý ±â±â ½ÃÀåÁ¤¼¼

  • PEST ºÐ¼®
  • »ýÅÂ°è ºÐ¼®
    • ¹ë·ùüÀÎÀÇ º¥´õ À϶÷

Á¦5Àå ½Å°æÁ¶Àý ±â±â ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ±âȸ
  • ÇâÈÄÀÇ µ¿Çâ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®

Á¦6Àå ½Å°æÁ¶Àý ±â±â ½ÃÀå : ½ÃÀå ºÐ¼®

  • ½Å°æÁ¶Àý ±â±â - ½ÃÀå °³¿ä
  • ½Å°æÁ¶Àý ±â±â - ½ÃÀå°ú ¿¹Ãø(-2030³â)

Á¦7Àå ½Å°æÁ¶Àý ±â±â ½ÃÀå : ¼öÀÍ ºÐ¼® - À¯Çüº°(2020³â-2030³â)

  • ³»ºÎ
  • ¿ÜºÎ

Á¦8Àå ½Å°æÁ¶Àý ±â±â ½ÃÀå : ¼öÀÍ ºÐ¼® - ¿ëµµº°(2020³â-2030³â)

  • ³ú½ÉºÎÀڱؿä¹ý(DBS)
  • À§ÀüÀÚ±Ø(GES)
  • ô¼ö ÀÚ±Ø(SCS)
  • ¹ÌÁֽŰæÀÚ±Ø(VNS)
  • õ°ñ½Å°æÀÚ±Ø(SNS)

Á¦9Àå ½Å°æÁ¶Àý ±â±â ½ÃÀå : ¼öÀÍ ºÐ¼® - »ýüÀç·áº°(2020³â-2030³â)

  • ±Ý¼Ó
  • °íºÐÀÚ
  • ¼¼¶ó¹Í

Á¦10Àå ½Å°æÁ¶Àý ±â±â ½ÃÀå : ¼öÀÍ ºÐ¼® - ÃÖÁ¾»ç¿ëÀÚº°(2020³â-2030³â)

  • º´¿ø
  • Áø·á¼Ò
  • ÀçÅà ÇコÄɾî

Á¦11Àå ½Å°æÁ¶Àý ±â±â ½ÃÀå : ¼öÀÍ ºÐ¼® - Áö¿ªº°(2020³â-2030³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ¿µ±¹
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • Áß³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ Áß³²¹Ì

Á¦12Àå »ê¾÷ Á¤¼¼

  • ÇÕº´°ú Àμö
  • °è¾à, Á¦ÈÞ, ÇÕÀÛ »ç¾÷
  • ½ÅÁ¦Ç° Ãâ½Ã
  • »ç¾÷ È®´ë ¹× ±âŸ Àü·«Àû Àü°³

Á¦13Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷ÀÇ È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ÀÇ Æ÷Áö¼Å´×°ú ÁýÁßµµ

Á¦14Àå ½Å°æÁ¶Àý ±â±â ½ÃÀå : ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Boston Scientific Corporation
  • Abbott
  • LivaNova PLC
  • Nevro Corp
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Synapse Biomedical Inc.
  • Aleva Neurotherapetics SA
  • Bioventus
  • EnteroMedics Inc

Á¦15Àå ºÎ·Ï

BJH 24.05.21

According to our latest study on "Neuromodulation Devices Market Forecast to 2030 - Global and Regional Share, Trend, and Growth Opportunity Analysis - by Type, Application, Biomaterial, and End User," the market was valued at US$ 5.73 billion in 2022 and is expected to reach US$ 11.61 billion by 2030; it is estimated to register a CAGR of 9.2% from 2022 to 2030.

Neuromodulation devices are advanced medical instruments that can adjust the activity of the nervous system. The technology is used to treat movement disorders such as dystonia, Parkinson's disease, and tremor; tinnitus; obsessive-compulsive disorder; sensory disabilities; epilepsy; bladder control; headache; chronic pain; stroke; minimally conscious state; spasticity; and spinal cord injury.

According to the WHO, in 2022, the US recorded 50 million epilepsy cases, 1 billion migraine cases, and 400,000 spinal cord injury cases. Spinal cord stimulation is one of the most preferred techniques in treating chronic back pain, primarily due to the anatomical and functional abilities of the spinal cord nerves to control the sensation of pain. The incidence of spinal cord injuries has grown over the past decade. The National Spinal Cord Injury Statistical Center (NSCISC) 2021 fact sheet states that the annual incidence of spinal cord injuries is 60 cases per million. According to the article titled "Epidemiology of traumatic spinal cord injuries: a large population-based study," published in April 2022, the overall age-sex standardized incidence rate of traumatic spinal cord injuries was 26.5 per 1 million population, and the rates were related to age in both sexes. According to the same source, in elderly (>= 65 years) population, the rate is 59.2 and 23.3 per 1 million in males and females, respectively. Spinal cord stimulators can be useful in managing postoperative pain associated with spinal surgery. An increase in number of spinal cord surgeries propels the demand for spinal cord stimulators. Therefore, high incidence of spinal cord injuries in old age and adults stimulates the demand for neuromodulation devices.

By Application, Neuromodulation Devices Market-Based Insights

The neuromodulation devices market, by application, is segmented into deep brain stimulation (DBS), sacral nerve stimulation (SNS), gastric electrical stimulation (GES), spinal cord stimulation (SCS), and vagus nerve stimulation (VNS). The spinal cord stimulation segment held the largest market share in 2022 and is expected to record the highest CAGR in the market during 2022-2030. Spinal cord stimulation has been used for years and is advised for a growing number of conditions. Cervical and lumbar radiculitis, failed back surgery syndrome, complex regional pain syndrome, and neuropathy are a few conditions that the therapy can assist. Spinal cord stimulation is efficacious, safe, and cost effective in chronic pain management. Newer spinal cord stimulation technologies are expanding clinical indications such as visceral and ischemic pain, with potential for further improved efficacy.

By Biomaterial, Neuromodulation Devices Market -Based Insights

Based on biomaterial, the neuromodulation devices market is segmented into metallic, polymeric, and ceramic. In 2022, the metallic segment dominated the market share. However, the polymeric segment is likely to register the highest CAGR during 2022-2030. In neuromodulation devices, metallic biomaterials are frequently utilized, especially in electrodes and other parts that need to be highly durable and electrically conductive. Owing to their great strength-to-weight ratio and exceptional biocompatibility, titanium and its alloys are frequently used in neuromodulation devices.

Center for Disease Control and Prevention, and Brazilian Institute of Neuroscience and Neurotechnology are a few of the major primary and secondary sources referred to while preparing the report on the neuromodulation devices market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Neuromodulation Devices Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Neuromodulation Devices Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Neuromodulation Devices Market - Global Market Analysis

  • 6.1 Neuromodulation Devices - Global Market Overview
  • 6.2 Neuromodulation Devices - Global Market and Forecast to 2030

7. Neuromodulation Devices Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 7.1 Overview
  • 7.2 Internal
  • 7.3 External

8. Neuromodulation Devices Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 8.1 Overview
  • 8.2 Deep Brain Stimulation (DBS)
  • 8.3 Gastric Electrical Stimulation (GES)
  • 8.4 Spinal Cord Stimulation (SCS)
  • 8.5 Vagus Nerve Stimulation (VNS)
  • 8.6 Sacral Nerve Stimulation (SNS)

9. Neuromodulation Devices Market - Revenue Analysis (USD Million) - By Biomaterial, 2020-2030

  • 9.1 Overview
  • 9.2 Metallic
  • 9.3 Polymeric
  • 9.4 Ceramic

10. Neuromodulation Devices Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 10.1 Overview
  • 10.2 Hospitals
  • 10.3 Clinics
  • 10.4 Home Healthcare

11. Neuromodulation Devices Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Neuromodulation Devices Market Overview
    • 11.1.2 North America Neuromodulation Devices Market Revenue and Forecasts to 2030
    • 11.1.3 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Type
    • 11.1.4 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Application
    • 11.1.5 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Biomaterial
    • 11.1.6 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By End User
    • 11.1.7 North America Neuromodulation Devices Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Neuromodulation Devices Market
        • 11.1.7.1.1 United States Neuromodulation Devices Market, by Type
        • 11.1.7.1.2 United States Neuromodulation Devices Market, by Application
        • 11.1.7.1.3 United States Neuromodulation Devices Market, by Biomaterial
        • 11.1.7.1.4 United States Neuromodulation Devices Market, by End User
      • 11.1.7.2 Canada Neuromodulation Devices Market
        • 11.1.7.2.1 Canada Neuromodulation Devices Market, by Type
        • 11.1.7.2.2 Canada Neuromodulation Devices Market, by Application
        • 11.1.7.2.3 Canada Neuromodulation Devices Market, by Biomaterial
        • 11.1.7.2.4 Canada Neuromodulation Devices Market, by End User
      • 11.1.7.3 Mexico Neuromodulation Devices Market
        • 11.1.7.3.1 Mexico Neuromodulation Devices Market, by Type
        • 11.1.7.3.2 Mexico Neuromodulation Devices Market, by Application
        • 11.1.7.3.3 Mexico Neuromodulation Devices Market, by Biomaterial
        • 11.1.7.3.4 Mexico Neuromodulation Devices Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Neuromodulation Devices Market - Key Company Profiles

  • 14.1 Boston Scientific Corporation
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 14.2 Abbott
  • 14.3 LivaNova PLC
  • 14.4 Nevro Corp
  • 14.5 NeuroPace, Inc.
  • 14.6 NeuroSigma, Inc.
  • 14.7 Synapse Biomedical Inc.
  • 14.8 Aleva Neurotherapetics SA
  • 14.9 Bioventus
  • 14.10 EnteroMedics Inc

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦